CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
NDA 21-073/S007

Trade Name: Actos

Generic Name: pioglitazone HCl

Sponsor: Takeda Pharmaceuticals Inc.

Approval Date: April 25, 2001

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 21-073/S007

CONTENTS

Reviews / Information Included in this NDA Review.	
Approval Letter	X
Approvable Letter	
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	X

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 21-073/S007

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug
Administration
Rockville MD 20857

NDA 21-073/S-007

Takeda Pharmaceuticals North America
Attention: Robert M. Pilson, RPh
Manager, Regulatory Compliance
475 Half Day Road, Suite 500
Lincolnshire, IL 60069

Dear Mr. Pilson:

Please refer to your supplemental new drug application dated January 18, 2001, received January 19, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Actos™ (pioglitazone hydrochloride) Tablets, 15 mg, 30 mg, and 45 mg.

This "Supplement - Changes Being Effected in 30 Days," provides for the addition of [redacted] located in [redacted] to act as a packager for the drug product.

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call Ms. Jena Weber, Regulatory Project Manager, at (301) 827-6422.

Sincerely,

{See appended electronic signature page}

Stephen K. Moore, Ph.D.
Chemistry Team Leader I, for
Division of Metabolic and Endocrine Drug Products,
(HFD-510)
DNDC II, Office of New Drug Chemistry
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Stephen Moore
4/25/01 03:00:58 PM

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 21-073/S007

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW

Organization CDER/HFD-510 Division of Metabolism and Endocrine Drug Products	**NDA # 21-073** Approved: 21-JUL-1999
Name and Address of Applicant: Takeda Pharmaceuticals America Inc. 101 Carnegie Center, Suite 207 Princeton, NJ 08540 Phone: (609) 452-1113 x-4409 Fax: (609) 452-1218	**Supplement** SCM-007 Doc. 18-JAN-2001 Rec. 19-JAN-2001 **Name Of The Drug** Actos™ Tablets **Nonproprietary Name** Pioglitazone Hydrochloride Tablets
Supplement provides for the addition of [redacted] as a packager for the drug product, Actos Tablets.	**Amendment(s)** --

Pharmacological Category: Hypoglycemic Agent, treatment of NIDDM.	**How Dispensed** Oral Rx	**Supporting Documents** --
Dosage Form Tablets	**Potencies** 15-, 30- and 45-mg	

Chemical Name and Structure

Pioglitazone

$C_{19}H_{20}N_2O_3S \cdot HCl$
MW = 356.43 + 36.57 = 392.90



(±)-5[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione monohydrochloride

Comments: This Supplement –Changes Being Effected in 30 days- provides for the addition of [redacted] as a packager for Actos® Tablets. This is considered a moderate change (Guidance for the Industry, Changes to an approved NDA or ANDA, November 1999, pages 7 to 11), an a CBE in 30 days supplemental submission is adequate. A request for inspection was submitted on 30-JAN-2001. The facility, [redacted], was inspected on 06-APR-2001, and found acceptable by the Office District (copy of EER Detail Report dated 09-APR-2001 is attached). *Adequate information has been provided, and all regulatory requirements have been fulfilled.*

Conclusions and Recommendations: [redacted] has been found acceptable for the packaging of the drug product, Actos® (Pioglitazone) Tablets. From the chemistry point of view, this supplement can be approved. **Issue approval letter.**

Reviewer Name (and signature) **Date Completed:** 09-APR-2001

Xavier Ysern, PhD

R/D Init.

filename: /nda/21073s07.doc

DISTRIBUTION: Original: NDA 21-073 cc: HFD-510 Division File/ JWeber / SMoore/ XYsern

CBE-30 days
AP

FDA CDER EES
ESTABLISHMENT EVALUATION REQUEST
DETAIL REPORT

Application: NDA 21073/007
Stamp: 19-JAN-2001
Regulatory Due: 19-JUL-2001
Applicant: TAKEDA PHARMS
475 HALF DAY RD STE 500
LINCOLNSHIRE, IL 60069
Priority: 1P
Org Code: 510

Action Goal:
District Goal: 14-JUN-2001
Brand Name: ACTOS (PIOGLITAZONE HCL)15/30/45MG TABS
Estab. Name:
Generic Name: PIOGLITAZONE HCL

Dosage Form: (TABLET)
Strength: 15-, 30- AND 45-MG

Application Comment: THE NAME OF THE FACILITY [redacted] THIS FACILITY WOULD BE USED AS ADDITIONAL PACKAGING FACILITY FOR ACTOS TABLETS (on 15-FEB-2001 by X. YSERN (HFD-510) 301-827-6420)

FDA Contacts: X. YSERN (HFD-510) 301-827-6420 , Review Chemist
S. MOORE (HFD-510) 301-827-6430 , Team Leader

Overall Recommendation: ACCEPTABLE on 09-APR-2001 by J. D AMBROGIO (HFD-324) 301-827-0062

Establishment: [redacted]

DMF No: AADA:
Responsibilities: [redacted]
Profile: TCM OAI Status: NONE
Estab. Comment: [redacted] (on 08-FEB-2001 by M. GARCIA (HFD-322) 301-594-0095)

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	01-FEB-2001				YSERNX
SUBMITTED TO DO	01-FEB-2001	GMP			FERGUSONS
ASSIGNED INSPECTION	21-FEB-2001	PS			LJARRELL
INSPECTION PERFORMED	06-APR-2001		05-APR-2001		LJARRELL
THIS INSPECTION WAS LIMITED TO [redacted] NO FDA-483 WAS ISSUED.					
DO RECOMMENDATION	06-APR-2001			ACCEPTABLE INSPECTION	LJARRELL
EI DONE FOR [redacted] ON 4/5/01.					
OC RECOMMENDATION	06-APR-2001			ACCEPTABLE DISTRICT RECOMMENDATION	FERGUSONS

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Xavier Ysern
4/19/01 10:29:47 AM
CHEMIST

AP

Stephen Moore
4/23/01 03:11:37 PM
CHEMIST

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 21-073/S007

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 21-073/S-007

CBE-30 SUPPLEMENT

Takeda Pharmaceuticals
Attention: Robert M. Pilson
RPh Manager, Regulatory Compliance
475 Half Day Road Suite 500
Lincolnshine, IL 60069

Dear Dr. Pilson:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: ACTOS (pioglitazone) Tablets, 15, 30, 45mg

NDA Number: 21-073

Supplement Number: S-007

Date of Supplement: January 18, 2001

Date of Receipt: January 19, 2001

This supplemental application, submitted as a "Supplement - Changes Being Effected in 30 days" supplement, proposes the following change: to add

Unless we notify you within 60 days of our receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on March 20, 2001 in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be July 19, 2001.

Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplemental application should be addressed as follows:

U.S. Postal Service/Courier/Overnight Mail:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Metabolic and Endocrine Drug Products, HFD-510
Attention: Division Document Room 14B-19
5600 Fishers Lane
Rockville, Maryland 20857

If you have any questions, call me at (301) 827-6422.

Sincerely,

{See appended electronic signature page}

Jena Weber
Regulatory Project Manager
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

/s/

Jena Weber
2/1/01 09:47:10 AM